The Prevention and Treatment of Missing Data in Clinical Trials | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Background Proton-pump inhibitors (PPIs) are often prescribed in combination with
thienopyridines. Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We …

Recently, adaptive interventions have emerged as a new perspective on prevention and
treatment. Adaptive interventions resemble clinical practice in that different dosages of certain …

Background Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of
treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous …

Background Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects.
The long-term efficacy and safety of edoxaban as compared with warfarin in patients with …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose
cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by …

Background Acute coronary syndromes arise from coronary atherosclerosis with superimposed
thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa …

Background—Considerable variability in mortality risk exists among patients with ST-elevation
myocardial infarction (STEMI). Complex multivariable models identify independent …

Background The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial
infarction has not been established. We investigated the efficacy and safety of ticagrelor, a …